TRANSTHERA-B (02617) repurchased 5,500 shares on October 22 at a cost of approximately HK$47,200.
Transthera-B (02617) announced that on October 22, 2026, it repurchased 5,500 shares at a cost of approximately HK$47,200.
TRANSTHERA-B (02617) announced that on October 22, 2026, it repurchased 5,500 shares at a cost of approximately HK$47,200.
Related Articles
GRAND PHARMA (00512) proposes appointing Deloitte as the new auditor.
European molecular testing leader Qiagen (QGEN.US) accepts EQT acquisition offer: 46.50 per share, a 40.3% premium to its July share price.
TIANYU SEMI (02658) repurchased 22,100 shares on October 22 for HKD 999,400.
GRAND PHARMA (00512) proposes appointing Deloitte as the new auditor.
European molecular testing leader Qiagen (QGEN.US) accepts EQT acquisition offer: 46.50 per share, a 40.3% premium to its July share price.
TIANYU SEMI (02658) repurchased 22,100 shares on October 22 for HKD 999,400.
